Kai Health participated in ASPIRE 2026, held in Beijing, China, May 7–10, where it introduced its AI-powered embryo analysis software, Vita Embryo.

Under the theme “Journeying the Silk Road of Reproductive Care,” the conference brought together fertility specialists, embryologists, researchers, and industry representatives from across Asia-Pacific to discuss developments and clinical applications in assisted reproductive technology (ART).

At its booth, Kai Health presented Vita Embryo’s key features and clinical applications. The software analyzes embryo images captured during IVF treatment and provides information clinicians can reference when prioritizing embryos for transfer or cryopreservation.

Building on regulatory foundations in Singapore, India, and other Asian markets, Kai Health focused on expanding product adoption and research collaboration across the region. The company has already begun deploying Vita Embryo through a fertility clinic network in India and plans to expand across Asia-Pacific, including Australia.

Kai Health also delivered two oral presentations on embryo image-based AI. One examined AI pregnancy predictions alongside clinical factors such as endometrial thickness, while the other evaluated whether AI could distinguish embryo hatching patterns. The company said the studies demonstrated the technology’s potential for clinical applications.

Source: NEWSIS · By Jong-ho Song · Originally published in Korean · Published on May 14, 2026

Kai Health Steps Up Expansion into the Asia-Pacific Fertility Market with AI Embryo Analysis